País: Canadá
Idioma: inglés
Fuente: Health Canada
ACYCLOVIR
GLAXOSMITHKLINE INC
J05AB01
ACYCLOVIR
200MG
TABLET
ACYCLOVIR 200MG
ORAL
100
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0115506002; AHFS:
CANCELLED POST MARKET
2016-01-11
_2014-11-10/131-pristine-pm-zovirax.doc _ _ _ _ _ _ _ _ _ _Page 1 of 38_ PRODUCT MONOGRAPH PR ZOVIRAX ® Acyclovir Oral Suspension USP, 200 mg /5 mL Acyclovir Tablets USP, 200 mg Antiviral Agent GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Revision: November 10, 2014 Submission Control No: 177766 _©_ _2014 GlaxoSmithKline Inc. All Rights Reserved _ _ZOVIRAX is a registered trademark of GlaxoSmithKline Inc. _ _2014-11-10/131-pristine-pm-zovirax.doc _ _ _ _ _ _ _ _ _ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................9 DOSAGE AND ADMINISTRATION ..............................................................................10 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...............................................................................15 PHARMACEUTICAL INFORMATION .......................................................... Leer el documento completo